The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
CCL
Vol.
37
No.
8
August 29, 2014
- Arzerra Maintenance Therapy Extends PFS In Phase III Trial, Compared to Observation
- TCGA Researchers Discover Stomach Cancer Falls Into Four Distinct Molecular Subtypes
- FDA Approves Avastin Combination For Late-Stage Cervical Cancer
- Phase III Nexavar Trial Fails Primary Endpoint
- Phase II ThermoDox Trial Demonstrates Positive Response
- Researchers Find Two Types Of MCL Drug Resistance
- International Working Group Suggests Earlier Endpoints For HPV Vaccine Trials
- Phase III Kyprolis Trial Fails OS Primary Endpoint
- Researchers Plan to Extend Phase IIa Asonep Trial
- Study: Nine Years After Diagnosis 9.3% of Survivors Still Smoke
- NCI CTEP-Approved Trials For the Month of August
TCL
Vol.
40
No.
33
September 05, 2014
- Timeline Pinpoints the Role of Cancer Scandal In a Progression Leading to Perry’s Indictment
- Device Maker Threatens Legal Action Against Doctor Who Launched Campaign to End Power Morcellation
- CPRIT Awards $107.2 Million Round of Grants
- NCI Launches ALCHEMIST
- CAP Issues Active Surveillance Guidance For Prostate Cancer
- Health Groups Urge FDA To Regulate Tobacco Products, Including E-Cigarettes
- Obituaries: Jessie Gruman, 60, CFAH Founder and President; Jesse Leonard Steinfeld, 87, U.S. Surgeon General
- In Brief: George Weiner to become president of AACI
- Drug Approvals: FDA grants accelerated approval for Keytruda in metastatic melanoma
TCL
Vol.
40
No.
34
September 12, 2014
- Group Chairs Seek Role Running NCTN
- Tobacco Interests Contribute a Portion Of the $109 Million Raised by Stand Up To Cancer
- Guest Editorial: Learning from the Power Morcellation Fiasco: Government Must Do More to Regulate Devices
- AACR Urges FDA to Regulate High Risk Lab-Developed Tests
- Funding Opportunity: PanCAN Offering $4.1 Million in Research Grants
- In Brief: Albert and Mary Lasker Foundation announce 2014 award winners
TCL
Vol.
40
No.
35
September 19, 2014
- DePinho Will Not Meet With AAUP In Probe of Tenure Denial Dispute
- Officials: Poisoning Unrelated to MD Anderson; Critics Allege Dysfunction in Handling of Affair
- Sept. 9 NCAB Meeting: Varmus: Expect Another CR For Funding The NIH Through Mid-December
- AACR 2014 Cancer Progress Report: More Federal Funds Needed
- Funding Opportunities: AACR Accepting Submissions for Two Dream Team Grants
- In Brief: David Tweardy named head of internal medicine at MD Anderson
TCL
Vol.
40
No.
36
September 26, 2014
- Colorado Institutions Vying to Build First Carbon Ion Center in the U.S.
- Conversation with The Cancer Letter: Pat White: NIH Funding “Our Only Concern”
- Gonzalez-Angulo Found Guilty in MD Anderson Poisoning Case
- Guest Editorial “Gizmo Idolatry” and Marketing Da Vinci’s Radical Robot
- MD Anderson Expands Reach Into Florida, Ohio
- NCI Starts “Exceptional Responders” Study
- In Brief: Doug Ulman named CEO of Pelotonia
CCL
Vol.
37
No.
9
September 26, 2014
- Final Results from CLEOPATRA Phase III Trial Show Perjeta Increased OS 15.7 Months
- Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial
- Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials
- Phase III Trial: Panobinostat Increases PFS by Four Months
- Phase III Cyramza Trial Meets OS Primary Endpoint
- Phase III Xilonix Study Halted Following Unscheduled Analysis
- Cediranib/Olaparib Combination Nearly Doubles PFS in Phase II
- Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says
- NCI CTEP-Approved Trials For the Month of September
- Keytruda Granted Approval In Metastatic Melanoma
TCL
Vol.
40
No.
37
October 03, 2014
- Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker
- Conversation with The Cancer Letter: Scott Soefje: “These are Life-Saving Drugs. I’m Not Going To Stop Treating Patients, Right?”
- Fake Avastin, Paid for by Medicare, Administered to U.S. Patients
- Gonzalez-Angulo To Serve 10 Years In Poisoning Case
- FDA Publishes Two Guidances for Lab-Developed Tests
- Groups Push for CMS Coverage for LDCT Lung Screening
- Funding Opportunity: NYC-based Research Alliance Offering $200,000 Per Year for Young Investigators
- In Brief: Leonidas Platanias named director of Lurie Comprehensive Cancer Center
TCL
Vol.
40
No.
38
October 10, 2014
- NCI Failed to Publish Two Bypass Budgets As Funds Tightened and Sequestration Set In
- Guest Editorial: Andrew Vickers on PSA Skepticism, Rational and Irrational
- UT Board Announces Support for MD Anderson Tenure System
- Study: Drug Discounts Used For Wealthier Patients In Many 340B-Enrolled Hospitals
- In Brief: ESMO Names Annual Award Winners
- Drugs and Targets: Akynzeo approved for chemotherapy-related nausea